Sonnet BioTherapeutics Holdings (SONN): Price-to-Projected Revenue Ratio

SONN (Sonnet BioTherapeutics Holdings Inc.) - company brandmark

Management of Sonnet BioTherapeutics (SONN) involves binary risks and a dependence on investment. The laboratory develops targeted immunomodulators to combat terminal metastases, however, the R&D stage and lack of sales keep costs elevated. The issuer's forward P/S visualizes market expectations for future sales, while the value 8.90 denotes the current figure for this metric.

SONN Sonnet BioTherapeutics Holdings Inc.: Market Cap to Future Revenue Ratio in the range 07/04/2022 - 12/13/2025

Analytical breakdowns for Sonnet BioTherapeutics Holdings (SONN)

- stock exchange capitalization data:
Manufactured products of sonnetbio.com

Sonnet BioTherapeutics is advancing immuno-oncology while strictly adhering to bioethical standards and environmental safety principles regarding waste disposal. The ratio of current market value to projected annual revenue via the expected P/S metric allows for an assessment of capitalization fairness relative to future earnings, neutralizing time gaps between reports and alerting investors to the risk of overpayment during sharp price spikes.

Competitor analysis

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Corp IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (arcusbio.com) - Market Cap to Projected Revenue|Zymeworks Biopharmaceuticals (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tango Pharma (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune)|Forward Price to Sales LYEL|innate-pharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology|Compugen Limited (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech, Inc. - Forward Price to Sales|STRO (sutrobio.com) - Forward P/S Multiple|Forward P/S Multiple MiNK Therapeutics Inc.|Price-to-Projected Revenue Ratio werewolftx.com (HOWL)|IMMX: Future Price to Revenue|alxoncology.com - Forward Price-to-Revenue Multiple|CUE - Forward Price-to-Revenue Multiple|PDSB - Price-to-Projected Revenue Ratio|MAIA Biotechnology, Inc. (MAIA) - Forward Price-to-Revenue Multiple|LIMN: Forward P/S Multiple|LAVA Therapeutics N.V. (LVTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple NXTC|Forward P/S Multiple leaptx.com|Forward P/S Multiple INTS|Market Cap to Expected Sales Ratio Sensei Biotherapeutics, Inc.|Forward P/S Multiple TOVX (Theriva Corp)|Market Cap to Expected Sales Ratio gritstonebio.com (GRTS)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP